142 related articles for article (PubMed ID: 37451547)
1. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy.
Yang Z; Liu Y; Zhao K; Jing W; Gao L; Dong X; Wang Y; Han M; Shi C; Tang C; Sun P; Zhang R; Fu Z; Zhang J; Zhu D; Chen C; Jiang X
J Control Release; 2023 Aug; 360():718-733. PubMed ID: 37451547
[TBL] [Abstract][Full Text] [Related]
2. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
3. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
4. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
Lu F; Ma XJ; Jin WL; Luo Y; Li X
Front Immunol; 2021; 12():690565. PubMed ID: 34054880
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma.
Ma Y; Chen Y; Yan L; Cao HX; Han SY; Cui JJ; Wen JG; Zheng Y
Int J Med Sci; 2020; 17(10):1406-1414. PubMed ID: 32624697
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
8. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
9. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
10. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.
Yang C; You J; Pan Q; Tang Y; Cai L; Huang Y; Gu J; Wang Y; Yang X; Du Y; Ouyang D; Chen H; Zhong H; Li Y; Yang J; Han Y; Sun F; Chen Y; Wang Q; Weng D; Liu Z; Xiang T; Xia J
BMC Med; 2023 Aug; 21(1):327. PubMed ID: 37635247
[TBL] [Abstract][Full Text] [Related]
12. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
13. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma.
Guo J; Tang Q
Cancer Gene Ther; 2021 Nov; 28(10-11):1075-1087. PubMed ID: 33500535
[TBL] [Abstract][Full Text] [Related]
14. Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC.
Li B; Zhao T; Shao M; Cai J; Chen S; Chen X; Yang M; Zheng Y; Cui C; Guo S; Yang Z; Ren F; Jia H
Int Immunopharmacol; 2023 Nov; 124(Pt B):111025. PubMed ID: 37827056
[TBL] [Abstract][Full Text] [Related]
15. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
[TBL] [Abstract][Full Text] [Related]
16. [NKG2D CAR-T cells as an immunotherapy in hepatocellular carcinoma].
Roussine Codo G; Khennas S
Med Sci (Paris); 2020; 36(6-7):662-664. PubMed ID: 32614319
[No Abstract] [Full Text] [Related]
17. In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.
Ye Z; Chen J; Zhao X; Li Y; Harmon J; Huang C; Chen J; Xu Q
ACS Biomater Sci Eng; 2022 Feb; 8(2):722-733. PubMed ID: 35104103
[TBL] [Abstract][Full Text] [Related]
18. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
Zhai Y; He K; Huang L; Shang X; Wang G; Yuan G; Han ZG
Liver Int; 2022 Nov; 42(11):2524-2537. PubMed ID: 36002393
[TBL] [Abstract][Full Text] [Related]
19. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
Patra T; Cunningham DM; Meyer K; Toth K; Ray RB; Heczey A; Ray R
Mol Ther; 2023 Mar; 31(3):715-728. PubMed ID: 36609146
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
